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FOR THE STUDIES OF LEFT VENTRICULAR DYSFUNCTION (SOLVD) INVESTIGATORS# 
A total of 6,273 consecutive relatkly unseWed patients with 
heartWureorIeftventrkuIardysRmd&~~(~egc 
62*12ycprs,wanejeetioa~31*9%),~earanedin 
thestudkofLeftvcntrieular~i~LvD)~ 
overaperiodof14montk.MptientBwerefdbwedRPf~~ 
sfptUSalldboBpiQl~at1~.Iscbcmicbcprt- 
wastheunderlyiBgcauseof~ordyslundknhl=7o%of 
patkts,whereashpten&eheartdiseasewas- 
plmaluyinvol~~oldy7%.Therewere~~~ere~: 
theetMogyofheortRuorcamoagbWrsirndwhk73%of 
white8hadaniuchemkeWogyoff&ihWever!msoxdy36%of 
bhehs;32%ofblackshodahyperk&vecondithmvwsos~ 
4%olnbites.~dDtall-gcpr~rste~18%;19%of 
pntkeBhadb@#tal admMonsforheartfhihweaml27%either 
diedorhadahoqiiadn&ionforcon@vehearttWure 
during the 1st yeBr of fldlow=up. Facters related to l=year 
mortaliQ or haspital dmission f r congestive h art failure in- 
duded age, @ctie~ &a&n, diabetes meWus, atrial fibrillation 
and female gender. There was no difkence in mortality associ- 
atedwithconge&eheartfidhwoamongblacksandwhites,bnt 
hqital admissions for heart faike were more frequent in 
bladcs.Digita&anddhweticogentsn~:rethedragsmostoften 
used in these patie&, who were ofk i.?Wng many medi~titms ia 
relatientoseverltyofatqestiveheartfailuresymptemsand 
ejectien fkactien. Suqhiogly, angietensin-wnve~ enzyme 
inldbitersweretakenbyenly3O%efpahts,andasubstantW 
numberwerehatedbydrugsanWoversialiothepresenceefleft 
vewcuk~naadhealt~,snehascalciumcbalmel 
aatagenists and aatiarrhythmic or beta-adreaergic blo king 
agents. 
(J Am CoU Car&l 1993;22[Sup@e1nen.t A]:MA-9A) 
Congestive heart failure is a leadii cause of morbidity 
and mortality in industrialized nations. It is estimated that 
>2.5 million North Americans are a&ted and that 400,000 
new related events occur each year (1,2). Congestive h art 
failure is also a growing public health problem, ‘nainly 
because of aging of the population a d the increase in the 
incidence and prevalence of heart failure in the elderly. Age 
is also a major determinant of the high morbidity and mortality 
rates of congestive heart failure (3). Important data bout the 
natural history of heart failure were derived kom the Framing- 
ham Heart Study (4,5), but both the spectrum of underlying 
disease and its management may have changed since then. 
failure tread in several centers in the United States, 
Canada nd Belgium according to standards of clinical 
practice that were widely accepted before the results of the 
Cooperative North Scandiivian Enalapril Survival Study 
(CONSENSUS) and SOLVD trials (74). The purpose of
this report isto review recent SOLVD Registry data, assess- 
ing the influence ofcliical features on subsequent arly 
morbidity and mortality, the relation between clinical find- 
ings and ejection fraction and the patterns ofdrug use in 
patients with congestive h art Wure. 
The Studies of Left Ventricular Dysfunction (SOLVD) 
Registry (6) allows the characterization of the natural course 
of consecutive relatively unselected patients with heart 
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Study group. The rationale, design and methods of the 
SOLVD Registry have been described previously (6). 
Brietly, from January 1,1988 toFebruary 28,1989, a total of 
6,273 patients were recruited from 18 of the 23 clinical sites 
participating  the SOLVD trials. 
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Patients entered the SOLVD Registry if they had an 
eection fraction of r45% measured by radionuclide, cardiac 
catheterization or echocardiographic methods or ufter a 
hospital discharge diagnosis of congestive h art failure con- 
firmed by radiologic evidence of pulmonary venous conges- 
tion (one w more of the following: pulmonary venous 
redistribution, basal or perihilar vascular blurring, Kerley B 
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lines, alveolar or pulmonary edema nd pleural effusions 
judged secondary tocongestive heart failure). Most patients 
(n = 4,951, 7%) were eligible on the basis of ejection 
fraction only, 864 (14%) on the basis of a hospital discharge 
diagnosis of heart failure and 458 (7%) on both. 
Eligible patients fulfilling any of the following conditions 
were excluded: 1) nonvalvular congenital heart disease; 
2) acute myocardial infarction or revascularization within 
7 days; 3) noncardiac life-threatening diseases likely to 
signillcantly shorten survival; 4) lack of reliable means of 
contact for follow-up; aud 5) inability to give informed 
consent. All patients had to be 221 years of age; there was 
no upper age limit. 
Baseline demographic, clinical and laboratory data were 
obtained from the patients’ medical records. Vital status and 
hospital admissions at1 year were obtained by mail or tele- 
phone contact. At 1 year, vital status was available for 99% 
of patients and information  hospital admissions for %%. 
Statlstlcal nalysis. The significance of differences in total 
mortality, congestive heart failure-related hospital admis- 
sions and death or congestive heart failure-related hospital 
admissions was assessed forselected categorized variables 
using the log-rank &i-square statistic. The r lative signill- 
cance of potential risk factors was obtained from multivari- 
ate logistic regression models. 
RWlltS 
Patlent characteristic. (Table 1). Of the total group of 
6,273 patients in the SOLVD Registry, whites accounted for 
85.6% (5,368 patients) ofthe total study group and blacks for 
11.1% (695 patients). Roughly 3% (210 patients) belonged to 
other racial groups and were excluded from this analysis. 
Overall, 74% were men and 26% women. 
Mean age was 62 + 12 years and 59% of patients were 
~60 years of age. Women were older than men, among both 
whites and blacks (66.5 + 12.7 vs. 61.5 2 11.1 years and 
60.5 + 13.8 vs. 56.1 + 13.0 years, respectively; both p = 
0.0001). Blacks were younger than whites (57.9 -F 13.5 vs. 
62.7 2 11.7 years, p = 0.0001) and the proportion of women 
was higher among blacks than among whites (42% vs. 24%, 
p = 0.0801). Mean ejection fraction was 30.9 2 9.2% for all 
groups. Ejection fraction was lower in blacks than in whites 
(28.6 f 9.1 vs. 3132 f 9.2%, p = 0.0001). Ischemic heart 
disease was the underlying etiology of heart failure in 
approximately 70% of patients, whereas hypertensive h art 
disease was considered tobe primarily involved in only 7%. 
However, a history of hypertension was present in 43% of 
patients. Idiopathic dilated cardiomyopathy was responsible 
for 13% of cases and other etiologies such as valvular heart 
disease and secondary cardiomyopathy for 11%. There were 
striking differences in the etiology of heart failure among 
blacks and whites. Roughly 73% ofwhites had an ischemic 
origin of heart failure versus only 36% of blacks (p = 0.8001). 
Only 4% of whites had an hypertensive condition versus 32% 
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Table 1. SOLVD Registry: Patient Characteristics 
Age (yr) 
Ejection fraction (%) 
Gender 
Male 
Female 
Race 
White 
Black 
Etiology of heart failure 
Ischemic 
Hypertensive 
Idiopathic 
Other 
History of angina 
Prior myocardial infarction 
History of hypertension 
Diabetes mellitus 
Atrial fibrillation 
Regular alcohol use 
Current smoking 
62.2 f 12.0 
28.9 + 9.2 
4,468 
1,595 
5,368 (85.6) 
695 (11.5) 
4,160 (68.5) 
439 0.2) 
789 (12.9) 
682 (11.3) 
3,516 (60.0) 
3,756 (63.4) 
2,552 (43.4) 
1,378 (23.4) 
731 (13.8) 
1,814 (38.3) 
1,264 (33.5) 
(73.7) 
(26.3) 
Data are presented as mean value f SD or number (%) of patients. 
SOLVD = Studies on Left Ventricular Dysfunction. 
of blacks (p = 0.001). Other etiologies were equally distrib- 
uted. 
Approximately 80% of patients in the SOLVD Registry 
were in New York Heart Association functhal class I or II 
and 20% were in class III or IV. At physical examination, 
32% had pulmonary rales, 26% had edema nd 20% an 
elevated ju,w venous pressure. A thiid sound gallop and 
mitral rqygitation were reported in 17% and 15% of pa- 
tients, respectively, and atrial fibrillation was observed in 
14%. 
FoIlow-up events at 1 year. The total mortality rate at 
F year was 18%. Roughly 80% of deaths were of cardiovas- 
cular origin. Slightly >50% of these patients died of progres- 
sive congestive heart failure. In the SOLVD Registry, 1% 
of patients had ;:s nr more hospital admissions for heart 
faihtre and 27% either had died or were admitted to the 
hospital for congestive heart failure during the 1st year of 
follow-up (Fig. 1). 
Age markedly influenced all follow-up events including 
total mortality, mortality related to heart failure and hospital 
admissions for congestive h art failure or both (Fig. 2). This 
was true in both racial groups (Fig. 3A). For all these end 
points, the rate of events was relatively low in patients <55 
years of age and increased steadily thereafter (Fii. 2). 
Women had higher rates of all these vents at 1 year than 
did men: 22% versus 17% total mortality @ = O.Os), 12% 
versus 9% congestive h art fail-elated mortality @ = 
OM), 22% versus 17% hospital admissions for congestive 
heart faihtre (p = 0.05) and 33% versus 25% death or hospital 
admissions for congestive h art faihue @= 0.0001) (Fig. 1). 
These differences were observed in wbites only. Black men 
and women had comparable incidence rates of death or 
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hospital admission for congestive heart failure at 1 year (Fig. 
3B). 
There was no difference among blacks and whites in total 
mortality (19% vs.18%), cardiovascular mortality (13% vs.
15%) and mortality associated with progressive congestive 
heart faihue (9% vs. 10%) (Fig. 1). However, blacks were 
admitted to the hospital for progressive h art failure signif- 
icantly more often than were whites during the same time 
period (25% vs. 17%, p = 0.018) and when the end points of 
death or hospital dmission for congestive h art failure were 
combined, blacks had a hiier incidence ofthese vents than 
did whites: 35% versus 26% (p = 0.005). This was true at all 
ages @ii. 3A). 
Total mortality rates and the incidence of deaths or 
hospital admissions for congestive heart failure at 1 year 
increased markedly but similarly with decreasing ejection 
fraction in both racial groups (Fii. 3C). Total mortality rates 
7 
Figure 1. Iniluence of gender and race on follow-up 
events at 1 year in the total study group of 6,565 
patients inthe Studies on Left Ventricular Dysfimc- 
tion (SOLVD) Registry. Women (F) had sign% 
cantly higher ates of total mortality, mortality or 
hospital dmissions related to congestive h art fail- 
ure (CHF) and combined mortality and congestive 
heart faihue&ated hospital admissions at 1 year 
than did men (I@. Blacks (B> and whites 0 had 
similar total and congestive heart failure-related 
mortality rates at 1 year. However, hospital dmis- 
sions for heart faihue were twice as frequent in 
blacks as in whites and combined death and hospital 
admissions for heart failure were higher. *p = 0.05, 
**p = 0.01, **+p c 0.005. 
did not appear to be influenced by the origin of heart failure, 
but the incidence of death or hospital admissions for conges- 
tive heart failure was higher in patients with hypertensive 
and valvular heart disease than in those with ischemic heart 
disease in both racial groups (Fig. 3D). 
Relation betweca baselh~ characteristics and outcome (Ta= 
MO 2). Factors related to l-year mortality or hospital admis- 
sion for congestive heart failure included, in order of impor- 
tance, advancing age, decreasing ejection fraction, diabetes 
mellitus, chronic atrial fibrillation, female gender, etiology of 
heart failure (the odds of having an event increased from 
ischemic to hypertensive h art disease), cardiothoracic ratio 
(significant only for hospital admission for congestive heart 
failure), absence of prior myocardii infarction, history of 
hypertension, race (significant only for hospital admission 
and not for mortality) and history of angina (borderline 
signiticant only for risk of hospital admission). Age and 
Figure 2. Age markedly influenced all follow-up 
events, including total mortality, mortality or hos- 
pital admissions related to congestive h art failure 
(CHF) and combined mortality and congestive h art 
failure-related hospital admissions at 1 year. 
SOLVD = Studies on Left Ventricular Dysfunc- 
tion. 
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Figure 3. Influence ofage, gender, ejection fraction 
and etiology of congestive heart failure (CHF) on 
death or congestive heart failure-related hospital 
admissions at I year. HHD = hypertensive h art 
disease; ICMP = idiopathic cardiomyopathy; IHD = 
ischemic heart disease; Other = other etiologies; 
other abbreviations as in Fii I. 
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ejection fraction had the highest ranking order and the 
greatest odds ratios among these factors. 
In the multivariate analysis, age, ejection fraction, female 
gender, diabetes meliitus and atrial fibrillation were inde- 
pendently related to mortality, hospital admission for con- 
gestive heart failure and mortality plus hospital admission 
for congestive heart f ilure at 1 year in patients with isch- 
emit heart disease (roughly 70% of the SOLVD Registry 
population). 
Patterns ofmedication use in patients with congestive h art 
failure. Diuretic agents were the drugs most often used: 
they were taken by 62% of patients. Digitalis, long-acting 
nitrates and antiplatelet agents were taken with a similar 
frequency (45%, 40% and 40% of parients, respectively). 
One-third of patients were taking calcium channel blockers 
and slightly >30% were taking angiotensin-converting en- 
zyme inhibitors. Overall, 27% were treated with antiarrhyth- 
mic agents and 16% with beta-adrenergic blocking agents. 
Anticoagulant therapy was given to 15% of patients. 
As one might expect, patients with a lower ejection 
fraction and more congestive heart failure symptoms re- 
ceived more diuretic drugs, digitalis and angiotensin- 
converting enzyme inhibitors: among patients with an ejec- 
tion fraction <20%, 90% were taking diuretic drugs, 65% 
digitalis and 55% an angiotensin-converting enzyme inbibi- 
tor; among patients with an ejection fraction of 36% to 45%, 
45% were taking diuretic drugs, 30% digitalis and 20% an 
angiotensin-converting enzyme inhibitor. Simiiarly, as the 
number of symptoms ofheart failure increased, the propor- 
tion of patients treated with diuretic drugs, digitalis and 
TaJ_& 2. L:g-Rank Tests of Differences in Survival Curves and Odds Ratio for Selected Variables inthe SOLVD Registry 
Variable 
Death or CHF Hospital 
Death CHF Hospital Admission Admission 
Odds Ratio D Value Odds Ratio p Value OddSRiitiO p Value 
Age 1.48 < 0.ooo1 1.31 < 0.0001 1.44 < O.aoOl 
Gender (MIF) 0.70 < 0.ooo1 0.75 < 0.001 0.67 < O.oool 
Race (w/B) 0.91 NS 1.33 c 0.0001 1.09 c 0.ooo1 
Ejection fractioa 1.56 c 0.oaO1 1.64 c 0.0001 1.66 c 0.ooo1 
Atrial fibrillation (Y/N) 1.81 c 0.ooo1 1.39 c 0.001 1.76 < o.omU 
Cardiothomcic ratio NS c o.tmO1 < 0.ooo1 
Dies mellitus (y/N) 1.37 c 0.0001 1.78 c O.lMOl 1.63 c O.tmOl 
Etiology of CHF (ischemiclothers) 1.11 c 0.05 I.14 c 0.MO1 I.14 c 0.0001 
Iviyocardial nfarction (YIN) 0.79 c 0.05 0.73 c 0.OlJO1 0.72 c o.aNl1 
Hypertension (u/N) I.14 NS I .27 c 0.01 I.24 c 0.001 
Angina WN 8.8i3 N3 0.85 c 0.05 0.83 c 0.05 
Alcohol (Y/N) 0.86 c 0.05 0.94 NS 0.89 NS 
Smoker (YIN) 0.76 NS 0.97 NS 0.82 NS 
For continuous variables, the following dichotomization was used for the calcihtior of odds ratios: age 265 vs. ~65 years: ejection fraction <35% vs. 235% 
cardiothomcic ratio 250 vs. ~50. B = black CHF = congestive h art failure; F = female; M = male; N = no; SOLVD = Shldies in Left ventricular DySfuaction; 
W = white; Y = yes. 
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angiotensin-converting e zyme inhibitors increased. The 
presence and severity of heart failure did not infhrence 
administration f nitrates and antiarrhythmic agents but 
showed an inverse relation to the use of beta-blockers and 
calcium channel blockers. 
Fewer patients with ischemic heart disease useddiuretic 
drugs, digitalis and angiotensin-converting enzyme inhibi- 
tors *compared with patients with heart failure of other 
etiologies. Conversely, more patients with ischemic heart 
disease were treated with long-acting nitrates, beta-blockers 
and especially calcium channel blockers. An&rhythmic 
drug use had a similar f equency in all groups. 
Discussion 
m factors. In the SOLVD Registry, the occur- 
rence of left ventricular dysfunction or congestive heart 
failure, or both, increased steadily with age. The mean age of 
the patients was 62 years; 59% were 260 years of age, and 
age clearly influenced all follow-up events, particularly mor- 
tality and hospital admissions due to congestive heart f il- 
ure. The Fram&ham Heart Study (4,5) showed that heart 
failure increases progressively with age, from a prevalence 
of~l%inthoseaged50to59yearstoaprev~en~ofal~ 
in persons 80 to 89 years. The incidence of new onset of 
heart faihue also increased dramatidy with advancing age. 
Heart faihue is thus a growing problem in our population 
because age is increasing. However, it is not clear whether 
advancing age is a primary determinant of prognosis or 
whether it reflects greater impairment of left ventricular 
function because major risk factors of left ventricular dys- 
function, such as hypertension, coronary artery disease and 
diabetes mellitus, are closely related to age. 
In multivariate analysis, age, ejection fraction, female 
gender, diabetes mellitus and atrial fibrillation are indepen- 
dently related to mortality, and hospital admission or death 
related to congestive heart failure, at least in patients with 
ischemic heart disease, which is the preponderant etiology of 
congestive heart failure in whites. Thus, patients wi hthese 
risk factors represent subgroups that require earlier detec- 
tion and more aggressive treatment. 
In The Framingham Heart Study (4,5), hypertension was 
the most frequent cause of congestive heart failure. In the 
SOLVD Registry, an average of 40% of patients had a 
history of arterial hypertension, but only 7% had cardio- 
myopathy secondary to h pertension alone. Coronary heart 
&ZX now represents he principal cause of congestive 
heart failure (70% of patients), perhaps because of better 
treatment of hypertension and the reduction of mortality 
from acute myocardial infarction and coronary artery 
disease (3), leading to an increased prevalence of impaired 
left ventricular function. This appears to be true for whites 
only. In blacks, coronary heart disease is nvolved in only 
one thud of cases and hypertensive h art disease is found 
in another third. Heart faihue or left ventricular dys- 
function, or both, also occurs earlier in blacks than in 
whites: at a mean age of 58 years in blacks versus 63 years 
in whites. 
Our data also show that total mortality and deaths asso- 
ciated with progressive congestive heart faihue are similar 
among blacks and whites, in contrast o data from the 
National Center for Health Statistics in the United States (3) 
between 1970 and 1985 that ageadjusted morbidity and 
mortality rates from heart failure are higher in blacks than in 
whites. It is possible that this shift between 1980 and now is 
the result of better hypertension control and a greater impact 
of therapy in blacks. For example, between 1970 and 1978, 
the mortality from heart failure decreased by ~16% in 
blacks, whereas no such trend was seen in whites (3). 
However, in the SOLVD Registry, blacks still have an 
increased incidence of hospital admissions for heart failure: 
blacks were admitted to he hospital twice as frequently as 
whites. That may be due in part to the greater incidence of 
hypertensive h art disease in blacks, which was associated 
with a greater rate of hospital admission than for ischemic 
heart disease. However, if one compares only patients with 
hypertensive h art disease, blacks still have an increased 
incidence of hospital admission for heart failure. Another 
explanation. may be the lower left ventricular ejection frac- 
tion that has been associated with higher ates of hospital 
admission. 
An increase in all event rates was demonstrated at 1 year 
in white but not in black women. This included increased 
total mortality and heart failure-related mortality nd hospi- 
tal admission rates in comparison with men. The reasons for 
the higher morbidity and mortality rates in white women 
than in white men are unknown. 
Drug therapy. Diuretic and digitalis therapy are the main- 
stay in heart failure treatment. Multidrug theravj is common 
and a substantial number of patients are maintained on drug 
therapy that is controversial in the presence of left ventric- 
ular dysfunction and heart failure (calcium channel blockers, 
antiarrhythmic agents and beta-blockers). Digitalis, which 
was very widely used, may also be questionable in the 
presence of symptomless ventricular dysfunction or in pa- 
tients without atrial fibrillation. Only 30% of patients in the 
SOLVD Registry received an angiotensin-converting en- 
zyme inhibitor. With the recognition that these drugs pre- 
vent heart failure and prolong survival (7,&), they will 
undoubtedly be used more frequently inthese patients inthe 
future. 
Conelnslons. The SOLVD Registry has identified several 
factors that are related to l-year mortality or hospital dmis- 
sion fdr congestive heart f ilure-mainly age, ejection fiuc- 
tion, diabetes me!!itus, atrial fibrillation and female g nder. 
Because heart failure is an end stage of heart disease that 
ensues after the organism has exhausted all its compensatory 
mechanisms and because, once overtly manifest, remains an 
extremely lethal condition (9), early detection and more 
aggressive treatment will probably help to improve the 
prognosis of these patients. 
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